![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: John Wiley & Sons Inc
E-ISSN: 1097-0045|75|8|798-805
ISSN: 0270-4137
Source: THE PROSTATE, Vol.75, Iss.8, 2015-06, pp. : 798-805
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Safety and efficacy of 2‐weekly cabazitaxel in metastatic castration‐resistant prostate cancer
BJU INTERNATIONAL, Vol. 121, Iss. 2, 2018-02 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
MiR200c targets IRS1 and suppresses prostate cancer cell growth
THE PROSTATE, Vol. 75, Iss. 8, 2015-06 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Methylselenocysteine preventing castration‐resistant progression of prostate cancer
THE PROSTATE, Vol. 75, Iss. 9, 2015-06 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Role of Immunotherapy in Castration‐Resistant Prostate Cancer (CRPC)
BJU INTERNATIONAL, Vol. 113, Iss. 3, 2014-03 ,pp. :